Caplin Point Subsidiary Receives GMP Certification from Colombia's INVIMA
Caplin Point Laboratories Ltd 路 Others (Uncategorized) 路 01 Sept 2026, 11:34 pm
Caplin Point Subsidiary Receives GMP Certification from Colombia's INVIMA Caplin Point Laboratories announced on Sep 01, '26 that its subsidiary, Caplin One Labs (COL), received Good Manufacturing Practices (GMP) compliance confirmation from Colombia's regulatory authority, INVIMA. The certification is for COL's manufacturing unit in Tamil Nadu, India. It covers the production of oncology drug products, including sterile lyophilized powder for injection (vials) and non-sterile tablets and capsules. This approval is a key regulatory milestone, facilitating market access and supply of these cancer treatments to Colombia. The formal certificate is expected shortly.
Original exchange filing (PDF)
More announcements from Caplin Point Laboratories Ltd
- Classification of US FDA Inspection at the facility of Caplin Steriles Limited, subsidiary of the Company as OAI 路 17 Nov 2026
- Audio Recording of Earnings call for the Quarter and half year ended September 30, 2026 路 13 Nov 2026
- Investor Presentation for the Earnings Call for the Quarter and half year ended September 30, 2026 路 12 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 12 Nov 2026
- Board Meeting Outcome for Meeting Held on November 12, 2026 路 12 Nov 2026
- Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 12 Nov 2026
- Analyst / investor Call for the quarter and half ended September 30, 2026 路 12 Nov 2026
- CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 12 Nov 2026
